Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients
Ritika Prasad, Brian Lu, Daniella Veloria, Emily Mui, Joanna Nelson, Gundeep Dhillon, Stanley Deresinski, Marisa Holubar, William Alegria
TL;DR
This paper explores improving antimicrobial stewardship by focusing on cytomegalovirus immune globulin use in immunocompromised patients.
Contribution
The study introduces a drug restriction program to enhance appropriate use of CMV-IGIV in immunocompromised patients.
Findings
A drug restriction program increased appropriate use of CMV-IGIV.
Targeting CMV-IGIV therapy shows potential as a stewardship strategy.
Immunocompromised patients benefit from improved antimicrobial stewardship approaches.
Abstract
Identifying actionable stewardship targets in immunocompromised patients is challenging due to limited data and high morbidity. One approach could be targeting therapy with limited evidence, like cytomegalovirus immune globulin (CMV-IGIV). We implemented a drug restriction program that increased appropriate use of CMV-IGIV, highlighting a unique stewardship opportunity in immunocompromised populations.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCytomegalovirus and herpesvirus research · Herpesvirus Infections and Treatments · Polyomavirus and related diseases